"Preview" Icon

Aclidinium

Tudorza Pressair, Bretaris Genuair, Eklira Genuair (aclidinium) is a small molecule pharmaceutical. Aclidinium was first approved as Tudorza Pressair on 2012-07-20. It is used to treat bronchial spasm and chronic obstructive pulmonary disease in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M1. Tudorza pressair’s patents are valid until 2029-03-13 (FDA).

$325 / month$3,000 / year

Clear

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Trade Name

Bretaris Genuair, Eklira Genuair

Common Name

aclidinium

ChEMBL ID

CHEMBL1194325

Indication

bronchial spasm, chronic obstructive pulmonary disease

Drug Class

Quaternary ammonium derivatives: muscarinic receptor antagonists

Image (chem structure or protein)

Aclidinium structure rendering

$325 / month$3,000 / year

Clear

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Every Drug Dataset Includes...

Full Drug Information

Including:

Trade name (FDA, EMA)

Drug common name

Description

Classification

Drug class

Image (chemical or protein structure)

Protein Data Bank ID

Structure (InChI/SMILES or Protein Sequence)

CAS-ID

RxCUI

ChEMBL ID

ChEBI ID

PubChem CID

DrugBank ID

Indications

Including:

Agency approved indications

Phase 1 Indications

Phase 2 Indications

Phase 3 Indications

Phase 4 Indications

MeSH identifiers

Ontology identifiers

Target Information

Including:

Agency Approved Targets

Alternative Targets

Gene name

Gene synonyms

NCBI Gene ID

Protein name

Protein synonyms

Uniprot ID

Orthologs

Clinical Variant Information

Including:

ClinVar ID

Target mutation

Effect

Evaluation date

PharmGKB level

Clinical Trial Information

Including:

NCT ID

Trial Timeline

Results

Phase

Expanded Access

Official Title

Sponsor

Indications / Phase Indications

Study Type

Enrollment

Inclusion Criteria

Exclusion Criteria

Links to Clinical Trials

Reimbursement Codes

Including:

ICD-10

ATC

HCPCS

Safety Information

Including:

Black Box Warnings

Adverse Events

Adverse Reactions

Expedite Criteria

Trend Information

Including:

Top, trending, and new metadata terms in the following categories:

Disease or Syndrome

Pharmacological Substances

Biological Entities

Laboratory Procedures

Commercial Information

Including:

Company (FDA, EMA)

Approval Date (FDA, EMA)

Exclusivity

Patent Expiration

Generics and Biosimilars (FDA, EMA)

Drug Labels

Economic Information

Including:

Company

Annual revenue

Quarterly revenue

Global sales

US sales

Non-US sales

Full dataset compatible with-

SQL logo
SQL for web applications
<strong>R</strong> for statistical modeling
R for statistical modeling
Spotfire and tableau logos
Spotfire & Tableau for visualization
<strong>CSV</strong> export file format
CSV export file format
JSON logo
JSON export file format
XLSX logo
XLSX export file format

Continually updated information available as a yearly subscription for individual drug-of-interest.

$325 / month$3,000 / year

Clear

Schedule a demo to see what you get or contact us for additional or enterprise purchasing options.